JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2019, 68(4):173-179 | DOI: 10.36290/csf.2019.020

Nephroprotective effect of N-acetylglucosamine in rats with acute kidney injury

Sergii K. Shebeko*, Igor A. Zupanets, Olha O. Tarasenko
Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine

The article presents the results of the study of the nephroprotective effect of N-acetylglucosamine (NAG) under the development of experimental acute kidney injury (AKI). The study was conducted on a model of acute glycerol nephrosis in rats. NAG was studied at a dose of 50 mg/kg at daily parenteral administration during 
1 week compared to quercetin, which was administered intraperitoneally at a dose of 34 mg/kg. The efficiency of the drugs was assessed by the functional state of animals, the renal excretory function and the nitrogen metabolism indices. The NAG effect on rats with AKI caused a reduction of the mortality rate, an increase in diuresis, a reduction of proteinuria, an increase in creatinine and urea excretion, which indicates the normalization of the renal excretory function and nitrogen metabolism. At the same time, NAG has statistically significantly exceeded the effect of quercetin in the majority of indices and, therefore, the level of efficiency. Thus, NAG is an efficient agent for AKI treatment, which can be used at parenteral route of administration.

Keywords: N-acetylglucosamine; nephroprotective effect; experimental acute kidney injury

Received: July 4, 2019; Accepted: August 16, 2019; Published: April 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Shebeko SK, Zupanets IA, Tarasenko OO. Nephroprotective effect of N-acetylglucosamine in rats with acute kidney injury. Čes. slov. farm. 2019;68(4):173-179. doi: 10.36290/csf.2019.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gilbert S. J., Weiner D. E., Bomback A. S., Perazella M. A., Tonelli M. National Kidney Foundation Primer on Kidney Diseases, 7th ed. Philadelphia: Elsevier 2018.
    2. Lerma E., Sparks M., Topf J. Nephrology secrets, 4th еd. Philadelphia: Elsevier 2019.
    3. Feehally J., Floege J., Johnson R. J., Tonelli M. Comprehensive clinical nephrology, 6th ed. Philadelphia: Elsevier 2019.
    4. Baynes J. W., Dominiczar M. H. Medical biochemistry, 5th ed. Philadelphia: Elsevier 2019.
    5. Lieberman M., Peet A. Marks' basic medical biochemistry: A clinical approach, 5th еd. Philadelphia: Wolters Kluwer 2018.
    6. Morita H., Yoshimura A., Kimata K. The role of heparan sulfate in the glomerular basement membrane. Kidney International 2008; 73, 247-248. Go to original source... Go to PubMed...
    7. Shebeko S. K., Zupanets I. A. Study of the pharmacological properties of some glucosamine derivatives under conditions of development of experimental autoimmune glomerulonephritis. Klìnìčna farmacìâ 2006; 10(2), 31-35 (in Ukrainian).
    8. Zupanets I. A., Shebeko S. K. The influence of experimental therapy on the dynamics of endogenous glucosamine content in laboratory animals with nephropathy. Eksp. Klin. Farmakol. 2006; 69(6), 40-42 (in Russian).
    9. Chen J. K., Shen C. R., Liu C. L. N-Acetylglucosamine: production and applications. Mar. Drugs 2010; 8, 2493-2516. Go to original source... Go to PubMed...
    10. Du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacology & Therapeutics 2014; 142(3), 362-374. Go to original source... Go to PubMed...
    11. Shebeko S. K., Zupanets I. A., Popov O. S. Tarasenko O. O., Shalamay A. S. Effects of quercetin and its combinations on health. In: Watson R. R., Preedy V. R., Sherma Z. (eds.) Polyphenols: mechanisms of action in human health and disease, 2nd ed. London: Academic Press 2018; 373-394. Go to original source...
    12. Guide for the care and use of laboratory animals, 8th ed. Washington: National Academies Press 2011.
    13. Sharp P., Villano J. S. The laboratory rat, 2nd ed. Boca Raton: CRC Press 2013. Go to original source...
    14. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union 2010; L276, 33-79.
    15. Bao Y. W., Yuan Y., Chen J. H., Lin W. Q. Kidney disease models: tools to identify mechanisms and potential therapeutic targets. Zoological Research 2018; 39(2), 72-86. Go to original source... Go to PubMed...
    16. Flecknell P. A. Laboratory animal anesthesia, 4th ed. Oxford: Academic Press 2015.
    17. Hart S. A., Hropot M., Greger R., Gögelein H., Bleich M. Activity on urinary tract. In: Vogel H. G. (ed.) Drug discovery and evaluation: Pharmacological Assays, 3rd ed. Berlin: Springer-Verlag 2008; 457-510. Go to original source...
    18. Koeppen B. M., Stanton B. A. Renal physiology, 6th ed. Philadelphia: Elsevier 2019.
    19. Speeckaert M., Delanghe J. Assessment of renal function. In: Turner N., Lameire N., Goldsmith D. J., Wineals C. G., Himmelfarb J., Remuzzi G. (eds.) Oxford textbook of clinical nephrology, 4th ed. Oxford: University Press 2016; 44-61.
    20. Islam M. A., Al-Shiha A. Foundations of biostatistics. Singapore: Springer 2018. Go to original source...
    21. Dudley W. N., Wickham R., Coombs N. An introduction to survival statistics: Kaplan-Meier analysis. J. Adv. Pract. Oncol. 2016; 7(1): 91-100. Go to original source... Go to PubMed...
    22. Park J., Lee S. Y., Ooshima A., Yang K. M., Kang J. M., Kim Y. W., Kim S. J. Glucosamine hydrochloride exerts a protective effect against unilateral ureteral obstruction-induced renal fibrosis by attenuating TGF-β signaling. J. Mol. Med. 2013; 91(11), 1273-1284. Go to original source... Go to PubMed...
    23. Hu J., Chen R., Jia P., Fang Y., Liu T., Song N., Xu X., Ji J., Ding X. Augmented O-GlcNAc signaling via glucosamine attenuates oxidative stress and apoptosis following contrast-induced acute kidney injury in rats. Free Radic. Biol. Med. 2017; 103, 121-132. Go to original source... Go to PubMed...
    24. Wang X., Xiong M., Zeng Y., Sun X., Gong T., Zhang Z. Mechanistic studies of a novel mycophenolic acid-glucosamine conjugate that attenuates renal ischemia/reperfusion injury in rat. Mol. Pharm. 2014; 11, 3503-3514. Go to original source... Go to PubMed...
    25. Fu Y., Lin Q., Gong T., Sun X., Zhang Z. R. Renal-targeting triptolide-glucosamine conjugate exhibits lower toxicity and superior efficacy in attenuation of ischemia/reperfusion renal injury in rats. Acta Pharmacol. Sin. 2016; 37, 1467-1480. Go to original source... Go to PubMed...
    26. Yang H., Song Y., Liang Y. N., Li R. Quercetin treatment improves renal function and protects the kidney in a rat model of adenine-induced chronic kidney disease. Med. Sci. Monit. 2018; 24, 4760-4766. Go to original source... Go to PubMed...
    27. Layal K., Perdhana I. S., Louisa M., Estuningtyas A., Soetikno V. The effects of quercetin on oxidative stress and fibrosis markers in chronic kidney disease rat model. Med. J. Indones. 2017; 26, 169-177. Go to original source...
    28. Vargas F., Romecín P., García-Guillén A. I., Wangesteen R., Vargas-Tendero P., Paredes M. D., Atucha N. M., García-Estañ J. Flavonoids in kidney health and disease. Front. Physiol. 2018; 9, Article 394. https://www.frontiersin.org Go to original source... Go to PubMed...
    29. Anand David A.V., Arulmoli R., Parasuraman S. Overviews of biological importance of quercetin: a bioactive flavonoid. Pharmacognosy Review 2016; 10(20), 84-89. Go to original source... Go to PubMed...
    30. Li Y., Yao J., Han C., Yang J., Chaudhry M. T., Wang S., Liu H., Yin Y. Quercetin, inflammation and immunity. Nutrients 2016; 8(3), 167-181. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.